drugset / Trial / NCT04316169
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
The hypothesis is that abemaciclib synergizes with autophagy inhibitor hydroxychloroquine (HCQ/ Plaquenil), inducing apoptosis leading to tumor regression.
Timeline
- Start
- 2021-10-21
- Primary completion
- 2027-01
- Completion
- 2028-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 150 mg | — |
| Subject | Anastrozole | Other / unclassified | — | — |
| Subject | Fulvestrant | Small molecule | — | — |
| Subject | Hydroxychloroquine | Small molecule | 200 mg | — |
| Subject | Hydroxychloroquine | Small molecule | 400 mg | — |
| Subject | Hydroxychloroquine | Small molecule | 600 mg | — |
| Subject | Letrozole | Other / unclassified | — | — |